Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2012

Jun 20, 2012

29977_dirs_2012-06-20_e26ddd33-732f-4341-870e-583f1cc28a5a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-06-18

Reporting Person: STAHL NEIL (SVP Res & Dev Sciences)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-06-18 Common Stock M 95079.0 $20.32 Acquired 154200.0 Direct
2012-06-18 Common Stock F 16757.0 $115.29 Disposed 137443.0 Direct
2012-06-18 Common Stock F 39411.0 $115.29 Disposed 98032.0 Direct
2012-06-19 Common Stock S 24848.0 $115.6 Disposed 73184.0 Direct
2012-06-19 Common Stock S 9080.0 $116.41 Disposed 64104.0 Direct
2012-06-19 Common Stock S 4383.0 $117.34 Disposed 59721.0 Direct
2012-06-19 Common Stock S 600.0 $118.1 Disposed 59121.0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-06-18 Non-Qualified Stock Option (right to buy) $20.32 M 95079.0 Disposed 2016-12-18 Common Stock (95079.0) Direct
2012-06-18 Non-Qualified Stock Option (right to buy) $115.29 A 16757.0 Acquired 2016-12-18 Common Stock (16757.0) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 5479.0 Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 24,848 shares of Company stock on June 19, 2012 at prices ranging from $115.23 to $115.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 19, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 9,080 shares of Company stock on June 19, 2012 at prices ranging from $116.01 to $116.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 19, 2012 at each separate price.

F4: Represents volume-weighted average price of sales of 4,383 shares of Company stock on June 19, 2012 at prices ranging from $117.00 to $117.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 19, 2012 at each separate price.

F5: Represents volume-weighted average price of sales of 600 shares of Company stock on June 19, 2012 at prices ranging from $118.00 to $118.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 19, 2012 at each separate price.

F6: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F7: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.